导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -19.31% | 3374/3712 |
| 近一周 | -4.12% | 3868/4228 |
| 近一月 | -5.99% | 3066/4196 |
| 近一季 | -3.11% | 1261/4044 |
| 近半年 | -22.12% | 3504/3824 |
| 近一年 | -23.91% | 3182/3446 |
| 近两年 | 35.65% | 1700/2399 |
| 近三年 | 5.69% | 1464/1802 |
| 成立以来 | 3.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.70% 2867/4961 |
-16.22% 4719/5312 |
- - |
- - |
| 2025 | 27.17% 1576/4813 |
5.28% 800/3635 |
5.04% 657/4076 |
22.12% 1691/4524 |
-5.84% 3630/4813 |
| 2024 | 6.89% 1713/3463 |
2.23% 805/2808 |
-16.25% 2725/3014 |
20.13% 753/3129 |
3.93% 749/3463 |
| 2023 | 20.67% 18/2656 |
39.01% 30/2280 |
6.07% 49/2385 |
-13.12% 2134/2515 |
-5.80% 1508/2655 |
| 2022 | -28.38% 1552/2207 |
-21.00% 1593/1919 |
-3.34% 1813/2016 |
-16.96% 1532/2113 |
12.95% 114/2208 |
| 2021 | -0.18% 743/1822 |
-8.02% 1073/1255 |
1.60% 1043/1330 |
-12.28% 1300/1466 |
21.77% 20/1822 |
| 2020 | 2.37% 920/1250 |
-5.71% 433/1028 |
18.73% 326/1067 |
1.23% 1029/1164 |
-9.67% 1162/1184 |
| 2019 | 27.01% 555/1092 |
31.33% 204/739 |
-15.53% 785/788 |
3.55% 245/850 |
10.56% 120/918 |
| 2018 | - - |
- - |
-17.35% 574/631 |
-12.52% 614/660 |
-7.55% 68/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证传媒ETF联接A VS. 长安沪深300非周期A(740101) |